SCHEMBL5658645

SCHEMBL5658645

O=C(c1ccc2c(c1)OCCO2)c1ccc2nc(Cl)nc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MAOB P27338 3/20 0.47
MAPT P10636 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TRPV1 Q8NER1 1/20 0.43
CHEK2 O96017 1/20 0.42
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
VNN1 O95497 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 3/20 0.40
USP2 O75604 2/20 0.40
POLB P06746 1/20 0.40
ATM Q13315 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14039064 0.84 CSNK2A2 (0.47) MAPTCSNK2A2CSNK2BTP53GAA
SCHEMBL3553199 0.81 CSNK2A2 (0.45) NPC1RAB9AMAPTCSNK2A2CSNK2B
SCHEMBL3553323 0.81 KDM4E (0.55) MAPTCSNK2A2CSNK2BGAAALDH1A1
SCHEMBL3559214 0.81 CSNK2A2 (0.45) MAPTCSNK2A2CSNK2BVNN1TP53
SCHEMBL5658015 0.81 NPSR1 (0.50) NPC1RAB9AMAOBMAPTNPSR1
SCHEMBL5656276 0.80 IP6K1 (0.51) NPC1RAB9AMAOBMAPTNPSR1
SCHEMBL3557898 0.79 HPGD (0.46) RAB9AMAPTNPSR1CSNK2A2CSNK2B
SCHEMBL5548743 0.79 DOT1L (0.55) NPC1RAB9AMAPTCSNK2A2CSNK2B
SCHEMBL5023267 0.77 CSNK2A2 (0.43) NPC1RAB9AMAPTCSNK2A2CSNK2B
SCHEMBL5782688 0.73 CSNK2A2 (0.46) CSNK2A2CSNK2BTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 NPC1 60/4885RAB9A 110/4885MAOB 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.